Organization
Novo Nordisk Canada Inc.
- Meetings this Parliament
- 41
- With MPs
- 20
- Since Nov 2021
- 102
- Active registrations
- 1
Most recent reported meeting: Sep 25, 2026.
Lobbying by Novo Nordisk Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingBills they've lobbied on
Named in their own descriptions of meetings or of their registration. Their words are quoted below each bill.
-
Bill S-201 4 mentions · latest Sep 18, 2026 In registration
“Advocating in support of Bill S-201, An Act respecting a national framework on sickle cell disease.”
-
Bill C-64 44-1 (previous Parliament) 17 mentions · latest Sep 18, 2026 In registration
“Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.”
Who they meet
Since the current Parliament opened.
MPs
- Karim Bardeesy Liberal 3
- Marcus Powlowski Liberal 2
- Sonia Sidhu Liberal 2
- Dan Mazier Conservative 2
- Matt Strauss Conservative 1
- Maggie Chi Liberal 1
- Marjorie Michel Liberal 1
- Jacques Ramsay Liberal 1
- Lori Idlout Liberal 1
- Parm Bains Liberal 1
- Michael Coteau Liberal 1
- Raquel Dancho Conservative 1
Institutions
- House of Commons17
- Innovation, Science and Economic Development Canada (ISED)9
- Health Canada (HC)9
- Privy Council Office (PCO)3
- Finance Canada (FIN)3
- Prime Minister's Office (PMO)2
- Intergovernmental Affairs Secretariat (IGA)2
- Treasury Board Of Canada Secretariat (TBS)1
Registrations in effect
In-house (organization) In effect since Sep 18, 2026
Filed by Iain Graham, General Manager
Lobbyists
-
Gabrielle Berard · Director, External Affairs
Former designated public office holder
Formerly Director of Parliamentary Affairs, Senate of Canada, Parliament of Canada (2017–2018)
Formerly Policy Advisor, Office of the Minister of Finance, Finance Canada (2011–2014)
- Luka Stevanovic · External Affairs Associate Director
- Michael Tucker · Patient Access Manager, Atlantic
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Canada Foundation for Innovation, Canadian Heritage (PCH), Canadian Human Rights Tribunal (CHRT), Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Research Council (NRC), Parks Canada (PC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (9)Hide details
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
- Advocating in support of Bill S-201, An Act respecting a national framework on sickle cell disease.
- Free trade agreements as they relate to the biopharmaceutical industry.
- Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
- Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
- Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
- Advocate for the implementation of a federal diabetes and obesity strategy.
- Advocate for the establishment of public-private partnerships to support chronic disease prevention.
Registration 963537-360616-26. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Vince Lamanna (55), Béatrice Clerc (26), Iain Graham (21).
-
Reported by Iain Graham · In-house (organization)
- Lori Idlout · Member of Parliament
Advocate for the establishment of public-private partnerships to support chronic disease prevention. Read more
Advocate for the implementation of a federal diabetes and obesity strategy.
-
Reported by Iain Graham · In-house (organization)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Read more
-
Reported by Iain Graham · In-house (organization)
- Jade Mallette · Director of Parliamentary Affairs, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
Advocating in support of Bill S-201, An Act respecting a national framework on sickle cell disease. Read more
Advocate for the establishment of public-private partnerships to support chronic disease prevention.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Eric Belair · Associate Assistant Deputy Minister, Health Canada (HC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
and 2 moreShow fewer
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Raquel Dancho · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Advocate for the implementation of a federal diabetes and obesity strategy.
-
Reported by Iain Graham · In-house (organization)
- Tom Kmiec · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Sonia Sidhu · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Dan Mazier · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Roy Karam · Senior Policy Advisor, Health Canada (HC)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
-
Reported by Iain Graham · In-house (organization)
- Michael Coteau · Member of Parliament
Advocating in support of Bill S-201, An Act respecting a national framework on sickle cell disease.
-
Reported by Iain Graham · In-house (organization)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Jacques Ramsay · Member of Parliament
Advocate for the implementation of a federal diabetes and obesity strategy. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Iain Graham · In-house (organization)
- Karim Bardeesy · Member of Parliament
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Martin Moen · Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
and 7 moreShow fewer
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Free trade agreements as they relate to the biopharmaceutical industry. Read more
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Iain Graham · In-house (organization)
- Marcus Powlowski · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
-
Reported by Iain Graham · In-house (organization)
- Marcus Powlowski · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
-
Reported by Iain Graham · In-house (organization)
- Helena Jaczek · Member of Parliament
Advocate for the implementation of a federal diabetes and obesity strategy. Read more
Advocate for the establishment of public-private partnerships to support chronic disease prevention.
-
Reported by Iain Graham · In-house (organization)
- Maggie Chi · Parliamentary Secretary to the Minister of Health, Health Canada (HC)
- Nora Draper · Parliamentary Secretary Assistant, Health Canada (HC)
Advocate for the implementation of a federal diabetes and obesity strategy.
-
Reported by Iain Graham · In-house (organization)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
-
Reported by Vince Lamanna · In-house (organization)
- Justine Frame · Special Assistant, Policy, Health Canada (HC)
- Sandenga Yeba · Director of Policy, Health Canada (HC)
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians. Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Vince Lamanna · In-house (organization)
- Karim Bardeesy · Parliamentary Secretary to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
-
Reported by Vince Lamanna · In-house (organization)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Sarah Lawley · Assistant Deputy Minister,, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry. Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Free trade agreements as they relate to the biopharmaceutical industry.
-
Reported by Vince Lamanna · In-house (organization)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes. Read more
Free trade agreements as they relate to the biopharmaceutical industry.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.